NO20021993L - Redoks-reversible HCV-proteiner med en konformasjon som ligner den native - Google Patents

Redoks-reversible HCV-proteiner med en konformasjon som ligner den native

Info

Publication number
NO20021993L
NO20021993L NO20021993A NO20021993A NO20021993L NO 20021993 L NO20021993 L NO 20021993L NO 20021993 A NO20021993 A NO 20021993A NO 20021993 A NO20021993 A NO 20021993A NO 20021993 L NO20021993 L NO 20021993L
Authority
NO
Norway
Prior art keywords
hcv proteins
native
conformation similar
similar
redox reversible
Prior art date
Application number
NO20021993A
Other languages
English (en)
Other versions
NO20021993D0 (no
Inventor
Alfons Bosman
Erik Depla
Geert Maertens
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2000/010499 external-priority patent/WO2001030815A1/en
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of NO20021993D0 publication Critical patent/NO20021993D0/no
Publication of NO20021993L publication Critical patent/NO20021993L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse gjelder HCV- proteiner hvori cysteinrester er reversibelt beskyttet under rensingen. Til slutt fører denne rense- fremgangsmåten til HCV-proteiner med biologisk aktivitet og en proteinkonformasjon som ligner den native konformasjon, og som presenterer epitoper som tilsvarer dem til det native protein. Foreliggende oppfinnelse gjelder også medikamentsøk- fremgangsmåter hvor disse HCV-proteinene anvendes, og diagnostiske og terapeutiske anvendelser, f.eks. vaksiner og medikamenter.
NO20021993A 1999-10-27 2002-04-26 Redoks-reversible HCV-proteiner med en konformasjon som ligner den native NO20021993L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99870225 1999-10-27
US16928899P 1999-12-07 1999-12-07
PCT/EP2000/010499 WO2001030815A1 (en) 1999-10-27 2000-10-25 Redox reversible hcv proteins with native-like conformation

Publications (2)

Publication Number Publication Date
NO20021993D0 NO20021993D0 (no) 2002-04-26
NO20021993L true NO20021993L (no) 2002-06-27

Family

ID=26153862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021993A NO20021993L (no) 1999-10-27 2002-04-26 Redoks-reversible HCV-proteiner med en konformasjon som ligner den native

Country Status (4)

Country Link
KR (1) KR20020047286A (no)
HK (1) HK1049847A1 (no)
IL (1) IL148931A0 (no)
NO (1) NO20021993L (no)

Also Published As

Publication number Publication date
IL148931A0 (en) 2002-09-12
KR20020047286A (ko) 2002-06-21
HK1049847A1 (zh) 2003-05-30
NO20021993D0 (no) 2002-04-26

Similar Documents

Publication Publication Date Title
Aguilar et al. β-Amino acid-containing hybrid peptides—new opportunities in peptidomimetics
DE602004011770D1 (de) Fusionsproteine
DK0458079T3 (da) Ultralyd-kontrastmidler, fremgangsmåde til deres fremstilling og deres anvendelse som diagnostika og terapeutika
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
MXPA05007211A (es) Composicion farmaceutica que comprende una region de fc de inmunoglobulina como un vehiculo.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE548388T1 (de) An den interleukin-4-rezeptor bindende antikörper
DE60203692D1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
DK1636261T3 (da) Thrombopoietinproteiner med forbedrede egenskaber
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
NO20021993L (no) Redoks-reversible HCV-proteiner med en konformasjon som ligner den native
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
HUP0203195A2 (hu) Redox reverzibilis HCV-fehérjék natívhoz hasonló konformációval
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
AR026246A1 (es) Proteinas hcv reversibles redox con conformacion de tipo nativo
NO20043459L (no) PIM-3-kinase som et mal for type-2 diabetes mellitus
HUP0301111A2 (hu) Potenciálisan immundomináns acetilkolin-receptor oligopeptideket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO900255L (no) Peptider med t-cellehjelperaktivitet.
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application